Company profile

Accelarator Nordic AB

Accelerator Nordic AB holds an active majority position in a number of Scandinavian Life Science companies active within Biotechnology, Pharmaceutical Drug Development and Medical Technology. The Accelerator Group addresses large growth markets such as medical imaging, oncology and drug delivery for orthopedic and dental implants. Products are in pre-clinical, clinical and initial commercialization phase. The business model is centered on partnering or out-licensing. Accelerator Nordic is a public company, traded on the Aktietorget exchange in Stockholm.

Business model

Accelerators business strategy is to create long term revenue by developing high-potential Life Science projects.

The development is driven by internal knowledge, a broad network and through cooperation with partners. The business model is centered on partnering or out-licensing with up-front payments, milestones and royalties based on successful development of the product.

Clinical and pre clinical verification

Development and verification of the different projects is done trough collaborations with consultants, academic and industrial partners. During the development process the focus is on commercial requirements and critical success factors.

Markets

Accelerator focuses on late stage projects that have a clear add-on value to existing markets and products.

Synergies

Accelerators ownership of projects comes from investments in subsidiaries. Accelerator utilizes synergies within the corporate group such as administrative functions, scientific expertise, business knowledge and resources for business development.